Abstract |
The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated. GSTP1 Ile(105)Val polymorphism was detected by TaqMan-MGB probe allelic discrimination method. Response to treatment was assessed by disease controlled rate. Time to progression, overall survival and toxicities were recorded. Final patient outcomes were as follows: the allele frequencies of GSTP1 were (105)Ile/(105)Ile 52%, (105)Ile/(105)Val 41% and (105)Val/(105)Val 7%. For patients with (105)Ile/(105)Ile and those with at least one (105)Val allele, disease control rate was 39% and 71% (P=0.026), respectively; median time to progression was 4.0 and 7.0 months (P=0.002); median overall survival time was 7.0 and 9.5 months (P=0.002). Neurological toxicity was more frequently occurred in patients with two (105)Ile alleles (P=0.005). In conclusion, patients with at least one (105)Val allele have better prognosis and response to oxaliplatin/5-FU-based regimen as first-line treatment for patients with advanced gastric cancer.
|
Authors | Qing-Fang Li, Ru-Yong Yao, Ke-wei Liu, Hong-Ying Lv, Tao Jiang, Jun Liang |
Journal | Journal of Korean medical science
(J Korean Med Sci)
Vol. 25
Issue 6
Pg. 846-52
(Jun 2010)
ISSN: 1598-6357 [Electronic] Korea (South) |
PMID | 20514304
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Organoplatinum Compounds
- Oxaliplatin
- GSTP1 protein, human
- Glutathione S-Transferase pi
- Fluorouracil
|
Topics |
- Adult
- Aged
- Alleles
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use, toxicity)
- Disease Progression
- Female
- Fluorouracil
(therapeutic use, toxicity)
- Gene Frequency
- Genotype
- Glutathione S-Transferase pi
(genetics)
- Humans
- Male
- Middle Aged
- Organoplatinum Compounds
(therapeutic use, toxicity)
- Oxaliplatin
- Polymorphism, Single Nucleotide
- Stomach Neoplasms
(drug therapy, genetics, mortality)
- Survival Analysis
- Time Factors
|